Investor Presentaiton
Private large
portfolio companies
EXTERNALLY VALUED
ӨӨ
08 RETAIL (PHARMACY) BUSINESS OVERVIEW (CONT'D)
Margin enhancement and strong
growth in para-pharmacy sales
Strong sales in para-pharmacy products of
GEL 54.1 million in 2Q21 (up 34.9% y-o-y),
with 31.8% gross profit margin.
Para-pharmacy sales have the strongest
margins and the share of para-pharmacy
sales in retail revenue reached 33.9% in
2Q21 (34.8% in 1Q21).
CASH FLOW
HIGHLIGHTS
Gross profit margin (%)
GEL million
24.5%
REVENUE
GEORGIA
CAPITAL
AVERAGE BILL SIZE & NUMBER OF BILLS ISSUED
Number of bills issued, million
25.5%
25.5%
25.4% 26.7% 25.1% 26.3% 24.2%
25.3
27.1
Same store growth (%)
28.8
27.6
5.7
7.2
13.4
13.7
NMF
9%
9%
6%
-6%
26%
6%
9%
800
679.4
614.7
600
518.6
184.7
450.3
176.9
+38.4%
134.5
400
113.9
+16.9%
318.8
372.8
102.4
199.0
82.9
494.7
200
437.8
143.8
336.4
384.1
56.1
36.6
235.9
270.4
107.2
142.9
2017
2018
2019
2020
2Q20
2Q21
1H20
1H21
■Retail
Distribution
Number of pharmacies
countrywide
270
296
309
299
329
EBITDA¹
GEL
18.5
18.8
17.6
16.8
16.5
14.3
13.3
13.4
2017
2018
2019
2020
2Q20
2Q21
1H20
1H21
CUSTOMER INTERACTIONS PER MONTH
2Q21
1H21
Operating cash
flow¹
GEL 16.1m
Operating leverage¹(%)
GEL 13.6m
Change y-o-y
-33.9%
-59.4%
NMF
EBITDA margin¹ (%)
7.8%
4.1% -1.4% -6.6%
2.6%
-2.8% -6.0%
c.0.8mln
Loyal customers
8.6%
10.1%
10.6%
10.4% 10.5% 10.1% 10.5%
8.9%
EBITDA to cash
conversion¹
150
79.8%
40.8%
20
Change y-o-y
-81.8ppts
-58.5ppts
Free cash flow¹
GEL million
100
-1.2%
GEL 11.8m
GEL 6.7m
70.4
65.3
+33.9%
52.2
38.9
50
million
10
33.6
33.2
20.1
15.0
Change y-o-y
-49.5%
-78.5%
Georgia Capital PLC | 1. Excluding IFRS16 impact
2.1
2.3
2.4
2.3
1.9
2.4
2.2
2.3
0
0
2017
2018
2019
2020
2Q20
2Q21
1H20
1H21
2017
2018
2019
2020
2Q20
2Q21
1H20
1H21
56View entire presentation